CCR4 and neoplasm: A preclinical experiment has shown that mogamulizumab, which antagonizes CCR4, can reduce tumor lung metastasis, and a Phase III clinical trial has demonstrated that antibodies targeting CCR4 are effective in treating patients with cutaneous T lymphoma.360